Literature DB >> 27420801

Priming Endothelial Cells With a Melanoma-Derived Extracellular Matrix Triggers the Activation of αvβ3/VEGFR2 Axis.

Edward Helal-Neto1,2, Renata M Brandão-Costa1, Roberta Saldanha-Gama1, Cristiane Ribeiro-Pereira1, Victor Midlej3, Marlene Benchimol3,4, Verônica Morandi2, Christina Barja-Fidalgo1.   

Abstract

The unique composition of tumor-produced extracellular matrix (ECM) can be a determining factor in changing the profile of endothelial cells in the tumor microenvironment. As the main receptor for ECM proteins, integrins can activate a series of signaling pathways related to cell adhesion, migration, and differentiation of endothelial cells that interact with ECM proteins. We studied the direct impact of the decellularized ECM produced by a highly metastatic human melanoma cell line (MV3) on the activation of endothelial cells and identified the intracellular signaling pathways associated with cell differentiation. Our data show that compared to the ECM derived from a human melanocyte cell line (NGM-ECM), ECM produced by a melanoma cell line (MV3-ECM) is considerably different in ultrastructural organization and composition and possesses a higher content of tenascin-C and laminin and a lower expression of fibronectin. When cultured directly on MV3-ECM, endothelial cells change morphology and show increased adhesion, migration, proliferation, and tubulogenesis. Interaction of endothelial cells with MV3-ECM induces the activation of integrin signaling, increasing FAK phosphorylation and its association with Src, which activates VEGFR2, potentiating the receptor response to VEGF. The blockage of αvβ3 integrin inhibited the FAK-Src association and VEGFR activation, thus reducing tubulogenesis. Together, our data suggest that the interaction of endothelial cells with the melanoma-ECM triggers integrin-dependent signaling, leading to Src pathway activation that may potentiate VEGFR2 activation and up-regulate angiogenesis. J. Cell. Physiol. 231: 2464-2473, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27420801     DOI: 10.1002/jcp.25358

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

Review 1.  3D Bioprinting: from Benches to Translational Applications.

Authors:  Marcel Alexander Heinrich; Wanjun Liu; Andrea Jimenez; Jingzhou Yang; Ali Akpek; Xiao Liu; Qingmeng Pi; Xuan Mu; Ning Hu; Raymond Michel Schiffelers; Jai Prakash; Jingwei Xie; Yu Shrike Zhang
Journal:  Small       Date:  2019-04-29       Impact factor: 13.281

Review 2.  Decellularization of tumours: A new frontier in tissue engineering.

Authors:  Elena García-Gareta; María Ángeles Pérez; José Manuel García-Aznar
Journal:  J Tissue Eng       Date:  2022-04-25       Impact factor: 7.940

3.  Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer.

Authors:  Yansong Lin; Chen Wang; Wen Gao; Ruixue Cui; Jun Liang
Journal:  Oncotarget       Date:  2017-06-27

4.  Recombinant RGD-disintegrin DisBa-01 blocks integrin αvβ3 and impairs VEGF signaling in endothelial cells.

Authors:  Taís M Danilucci; Patty K Santos; Bianca C Pachane; Graziéle F D Pisani; Rafael L B Lino; Bruna C Casali; Wanessa F Altei; Heloisa S Selistre-de-Araujo
Journal:  Cell Commun Signal       Date:  2019-03-20       Impact factor: 5.712

5.  Extracellular Matrix Derived from High Metastatic Human Breast Cancer Triggers Epithelial-Mesenchymal Transition in Epithelial Breast Cancer Cells through αvβ3 Integrin.

Authors:  Renata M Brandão-Costa; Edward Helal-Neto; Andreza M Vieira; Pedro Barcellos-de-Souza; Jose Morgado-Diaz; Christina Barja-Fidalgo
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

6.  Array Comparative Genomic Hybridization Analysis Reveals Significantly Enriched Pathways in Canine Oral Melanoma.

Authors:  Ginevra Brocca; Serena Ferraresso; Clarissa Zamboni; Elena M Martinez-Merlo; Silvia Ferro; Michael H Goldschmidt; Massimo Castagnaro
Journal:  Front Oncol       Date:  2019-12-12       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.